Licensed in 2003 from EpiCept Corporation for North America, the product was in phase II clinical development. Adolor expects to transition the program to EpiCept by the end of the year.
“In this case, we have decided that the company’s resources are better allocated to our other clinical and discovery research efforts,” said David Madden, interim president and CEO of Adolor Corporation.
“We are pleased to regain the full, worldwide control of LidoPAIN SP and remain very optimistic about the product candidate’s clinical and commercial potential,” remarked Jack Talley, president and CEO of EpiCept Corporation.
EpiCept said it expected to be in a position to initiate another phase III clinical trial for this product candidate in the US and Europe in the first half of 2007.